Citations

Clear

3057 citation(s) found for "Cd, Johnson".

IGF-I/IGFBP-3 ratio: a mechanistic insight into the metabolic syndrome
Sierra‐Johnson, Justo, Romero‐Corral, Abel, Somers, Virend K., Brismar, Kerstin , Hamsten, Anders, Fisher, Rachel M. , Hellénius, Mai‐Lis, López-Jiménez, Francisco , Mälarstig, Anders , Hellénius, Mai-Lis

Mayo Clinic

Clinical Science | October 6, 2008 | Volume: 116 | Issue: 6 | Pages: 507-512

10.1042/cs20080382 | PMID 18816247 Get It

Recent reports suggest that IGF (insulin-like growth factor)-I and IGFBP-3 (IGF-binding protein-3) have independent and opposing mechanistic effects on insulin. The aim of the present study was to assess the relationship between the IGF-I/IGFBP-3 ratio and the metabolic syndrome. We examined 3281 subjects (1463 men and 1818 women, aged 20–49 years), otherwise healthy adults, who participated in NHANES III (Third National Health and Nutrition Examination Survey), which has released measurements of IGF-I and IGFBP-3. Insulin resistance was estimated using the computer HOMA2 (homoeostatic model assessment 2) model. The updated ATP-III (Adult Treatment Panel III) definition of the metabolic syndrome was used. We applied adjusted logistic and linear regression models. After adjusting for age and race, men and women in the lowest quartile of the IGF-I/IGFBP-3 ratio were 3-fold more likely to meet the ATP-III definition of the metabolic syndrome and twice as likely to be insulin-resistant. Mean values of the IGF-I/IGFBP-3 ratio decreased significantly as the number of metabolic syndrome components increased (P<0.0001, as determined by ANOVA). The area under the ROC (receiver operating characteristic) curve for detecting insulin resistance using the IGF-I/IGFBP-3 ratio was 0.760, significantly improving upon either protein alone (P=0.01). In conclusion, the IGF-I/IGFBP-3 ratio is significantly associated with the metabolic syndrome. Calculating the ratio of these two proteins may provide insight into the metabolic syndrome clustering phenomenon.
Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups
Strauss, Gary M., Herndon, James E. , Maddaus, Michael A. , Johnstone, David W., Harpole, David H., Gillenwater, Heidi H., Watson, Dorothy, Sugarbaker, David J., Schilsky, Richard L. , Green, Mark R., Johnson, Elizabeth Anne , Vokes, Everett E.

Mayo Clinic

Journal of Clinical Oncology | September 22, 2008 | Volume: 26 | Issue: 31 | Pages: 5043-5051

10.1200/jco.2008.16.4855 | PMID 18809614 Get It

Purpose Adjuvant chemotherapy for resected non–small-cell lung cancer (NSCLC) is now accepted on the basis of several randomized clinical trials (RCTs) that demonstrated improved survival. Although there is strong evidence that adjuvant chemotherapy is effective in stages II and IIIA NSCLC, its utility in stage IB disease is unclear. This report provides a mature analysis of Cancer and Leukemia Group B (CALGB) 9633, the only RCT designed specifically for stage IB NSCLC. Patients and Methods Within 4 to 8 weeks of resection, patients were randomly assigned to adjuvant chemotherapy or observation. Eligible patients had pathologically confirmed T2N0 NSCLC and had undergone lobectomy or pneumonectomy. Chemotherapy consisted of paclitaxel 200 mg/m 2 intravenously over 3 hours and carboplatin at an area under the curve dose of 6 mg/mL per minute intravenously over 45 to 60 minutes every 3 weeks for four cycles. The primary end point was overall survival. Results Three hundred-forty-four patients were randomly assigned. Median follow-up was 74 months. Groups were well-balanced with regard to demographics, histology, and extent of surgery. Grades 3 to 4 neutropenia were the predominant toxicity; there were no treatment-related deaths. Survival was not significantly different (hazard ratio [HR], 0.83; CI, 0.64 to 1.08; P = .12). However, exploratory analysis demonstrated a significant survival difference in favor of adjuvant chemotherapy for patients who had tumors ≥ 4 cm in diameter (HR, 0.69; CI, 0.48 to 0.99; P = .043). Conclusion Because a significant survival advantage was not observed across the entire cohort, adjuvant chemotherapy should not be considered standard care in stage IB NSCLC. Given the magnitude of observed survival differences, CALGB 9633 was underpowered to detect small but clinically meaningful improvements. A statistically significant survival advantage for patients who had tumors ≥ 4 cm supports consideration of adjuvant paclitaxel/carboplatin for stage IB patients who have large tumors.
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping
Johnson, David C. , Corthals, Sophie L., Ramos, Christine, Hoering, Antje , Cocks, Kim , Dickens, Nicholas J. , Haessler, Jeff, Goldschmidt, H., Child, J. Anthony, Bell, Sue , Jackson, Graham , Baris, Dalsu , Rajkumar, S. Vincent , Davies, Faith E. , Durie, Brian G.M. , Crowley, John, Sonneveld, Pieter , Ness, Brian Van, Morgan, Gareth J. , Rajkumar, S Vincent , Davies, Faith E , Morgan, Gareth J

Mayo Clinic

Blood | September 20, 2008 | Volume: 112 | Issue: 13 | Pages: 4924-4934

10.1182/blood-2008-02-140434 | PMID 18805967 Get It

AbstractA venous thromboembolism (VTE) with the subsequent risk of pulmonary embolism is a major concern in the treatment of patients with multiple myeloma with thalidomide. The susceptibility to developing a VTE in response to thalidomide therapy is likely to be influenced by both genetic and environmental factors. To test genetic variation associated with treatment related VTE in patient peripheral blood DNA, we used a custom-built molecular inversion probe (MIP)–based single nucleotide polymorphism (SNP) chip containing 3404 SNPs. SNPs on the chip were selected in “functional regions” within 964 genes spanning 67 molecular pathways thought to be involved in the pathogenesis, treatment response, and side effects associated with myeloma therapy. Patients and controls were taken from 3 large clinical trials: Medical Research Council (MRC) Myeloma IX, Hovon-50, and Eastern Cooperative Oncology Group (ECOG) EA100, which compared conventional treatments with thalidomide in patients with myeloma. Our analysis showed that the set of SNPs associated with thalidomide-related VTE were enriched in genes and pathways important in drug transport/metabolism, DNA repair, and cytokine balance. The effects of the SNPs associated with thalidomide-related VTE may be functional at the level of the tumor cell, the tumor-related microenvironment, and the endothelium. The clinical trials described in this paper have been registered as follows: MRC Myeloma IX: ISRCTN68454111; Hovon-50: NCT00028886; and ECOG EA100: NCT00033332.
Differential diagnosis of suspected multiple sclerosis: a consensus approach
Miller, DH, Weinshenker, BG, Filippi, Massimo , Banwell, BL, Cohen, JA, Freedman, MS, Galetta, SL, Hutchinson, Michael , Johnson, RT, Kappos, Ludwig , Lublin, FD, McFarland, HF, Montalbán, Xavier , Panitch, Hillel, Richert, J, Reingold, Stephen C. , Polman, C.H., Weinshenker, Brian G. , Sl, Galetta, Kira, Jun‐ichi , Weinshenker, Brian G , Filippi, Massimo

Mayo Clinic

Multiple Sclerosis Journal | September 19, 2008 | Volume: 14 | Issue: 9 | Pages: 1157-1174

10.1177/1352458508096878 | PMID 18805839 Get It

Background and objectives Diagnosis of multiple sclerosis (MS) requires exclusion of diseases that could better explain the clinical and paraclinical findings. A systematic process for exclusion of alternative diagnoses has not been defined. An International Panel of MS experts developed consensus perspectives on MS differential diagnosis. Methods Using available literature and consensus, we developed guidelines for MS differential diagnosis, focusing on exclusion of potential MS mimics, diagnosis of common initial isolated clinical syndromes, and differentiating between MS and non-MS idiopathic inflammatory demyelinating diseases. Results We present recommendations for 1) clinical and paraclinical red flags suggesting alternative diagnoses to MS; 2) more precise definition of “clinically isolated syndromes” (CIS), often the first presentations of MS or its alternatives; 3) algorithms for diagnosis of three common CISs related to MS in the optic nerves, brainstem, and spinal cord; and 4) a classification scheme and diagnosis criteria for idiopathic inflammatory demyelinating disorders of the central nervous system. Conclusions Differential diagnosis leading to MS or alternatives is complex and a strong evidence base is lacking. Consensus-determined guidelines provide a practical path for diagnosis and will be useful for the non-MS specialist neurologist. Recommendations are made for future research to validate and support these guidelines. Guidance on the differential diagnosis process when MS is under consideration will enhance diagnostic accuracy and precision.
Detection of Occult Colonic Perforation Before CT Colonography After Incomplete Colonoscopy: Perforation Rate and Use of a Low-Dose Diagnostic Scan Before CO2Insufflation
Hough, David M., Kuntz, Martin A., Fidler, Jeff L. , Johnson, C. Daniel, Petersen, Bret T. , Kofler, James M., Fidler, Jeff L. , Fletcher, Joel G.

Mayo Clinic

American Journal of Roentgenology | September 19, 2008 | Volume: 191 | Issue: 4 | Pages: 1077-1081

10.2214/ajr.07.2746 | PMID 18806146 Get It

Behavioral Interventions to Prevent Childhood Obesity: A Systematic Review and Metaanalyses of Randomized Trials
Vickers, Kristin S. , Ehrlich, Angela, McGovern, Lauren, Johnson, Jonathan N. , Singhal, Vibha , Paulo, Remberto, Hettinger, Allison, Erwin, Patricia J., Montori, Víctor M. , Kamath, Celia , Montori, Victor M

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 10, 2008 | Volume: 93 | Issue: 12 | Pages: 4606-4615

10.1210/jc.2006-2411 | PMID 18782880 Get It

Treatment of Pediatric Obesity: A Systematic Review and Meta-Analysis of Randomized Trials
McGovern, Lauren, Johnson, Jonathan N. , Paulo, Remberto, Hettinger, Allison, Singhal, Vibha , Erwin, Patricia J., Montori, Víctor M. , Kamath, Celia , Montori, Victor M

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 10, 2008 | Volume: 93 | Issue: 12 | Pages: 4600-4605

10.1210/jc.2006-2409 | PMID 18782881 Get It

Phase III, Double-Blind Study of Depot Octreotide Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy: Results of North Central Cancer Treatment Group N00CA
Martenson, James A., Halyard, Michele Y. , Sloan, Jeff A. , Proulx, Gary M., Miller, Robert C. , Deming, Richard L., Dick, Stephen J., Johnson, Harold A., Tai, Tianxiang, Keit, Joan, Stien, Kathy J., Atherton, Pamela J., Atherton, Philip J. , Zhu, Angela W. , Atherton, Pamela J., Atherton, Philip J.

Mayo Clinic

Journal of Clinical Oncology | September 3, 2008 | Volume: 26 | Issue: 32 | Pages: 5248-5253

10.1200/jco.2008.17.1546 | PMID 18768432 Get It

Purpose To assess the effectiveness of depot octreotide for the prevention of diarrhea during pelvic radiation therapy. Patients and Methods Patients receiving pelvic radiation therapy (planned minimum dose, 45 Gy; 1.7 to 2.1 Gy daily) were eligible for the study. From May 10, 2002, through October 14, 2005, 125 patients were randomly allocated in a double-blind fashion to receive octreotide (100 μg, administered subcutaneously on day 1, followed by depot octreotide, 20 mg, administered intramuscularly on days 2 and 29; n = 62) or to receive a placebo (n = 63). Results Grade 0, 1, 2, and 3 diarrhea were observed in 18%, 31%, 31%, and 21% of patients in the octreotide arm, respectively, and in 25%, 32%, 22%, and 21% of patients in the placebo arm, respectively (P = .64). Grade 0, 1, 2, and 3 abdominal cramps were observed in 32%, 45%, 21%, and 2% of patients receiving octreotide, respectively, and in 51%, 24%, 21%, and 5% of patients receiving the placebo, respectively (P = .053). Some patient-reported symptoms were worse in the octreotide group, including nocturnal bowel movements (70% v 45%; P = .004), clustering of bowel movements (90% v 69%; P = .004), and bleeding with bowel movements (57% v 35%; P = .01). Conclusion As administered in this study, octreotide did not decrease diarrhea during pelvic radiation therapy. Some gastrointestinal symptoms were worse in patients treated with octreotide. Octreotide is not indicated for prevention of diarrhea during pelvic radiation therapy.
An HLA-DR–Degenerate Epitope Pool Detects Insulin-like Growth Factor Binding Protein 2–Specific Immunity in Patients with Cancer
Kalli, Kimberly R., Krco, Christopher J., Hartmann, Lynn C., Goodman, Karin M., Maurer, Matthew J. , Yu, Chao, Johnson, Elliot M., Erskine, Courtney L. , Wettstein, Peter J., Fikes, John, Beebe, Melanie, Ishioka, Glenn, Knutson, Keith L. , Disis, Mary Lenora , Knutson, Keith L. , Maurer, Matthew

Mayo Clinic

Cancer Research | June 16, 2008 | Volume: 68 | Issue: 12 | Pages: 4893-4901

10.1158/0008-5472.can-07-6726 | PMID 18559537 Get It

AbstractRecent studies have shown the importance of helper CD4 T cells in initiating and sustaining tumor-specific CD8 T-cell immunity. This has paved the way for identifying MHC class II epitopes that could be incorporated into class I–based vaccines. In this study, the goal was to identify an HLA-DR–degenerate epitope pool derived from insulin-like growth factor binding protein 2 (IGFBP-2). IGFBP-2, a regulator of insulin-like growth factor action, is overexpressed in the majority of breast and ovarian cancers. Using algorithms, we predicted 29 HLA-DR1–binding epitopes. Binding assays targeting 15 different HLA-DRs revealed that 10 epitopes were degenerate, binding to at least four different HLA-DR variants. An IFN-γ enzyme-linked immunosorbent spot assay was used to assess immunity to these 10 epitopes in 48 patients with either breast or ovarian cancer and 18 controls. Elevated T-cell immunity in patients was detected in 4 of the 10 epitopes (IGFBP2.17, IGFBP2.22, IGFBP2.249, and IGFBP2.293). The cumulative T-cell frequency of these four epitopes was elevated in patients relative to controls. All four peptides are naturally processed and presented to CD4 T-cells. The degenerate pool of peptides covers nearly 80% of patients and may be useful for augmenting CD4 T-cell immunity in patients undergoing immunization. [Cancer Res 2008;68(12):4893–901]
Prognostic importance of weight loss in patients with coronary heart disease regardless of initial body mass index
Sierra‐Johnson, Justo, Romero‐Corral, Abel, Thomas, Randal J. , Squires, Ray W. , Allison, Thomas G. , Somers, Virend K. , López-Jiménez, Francisco , Thomas, Randal

Mayo Clinic

European Journal of Cardiovascular Prevention & Rehabilitation | June 4, 2008 | Volume: 15 | Issue: 3 | Pages: 336-340

10.1097/hjr.0b013e3282f48348 | PMID 18525390 Get It